Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥30.00 - ¥97.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥3.33B
Enterprise Value¥2.26K
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.80
Shares Outstanding104,124,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenome-modulation PlatformModalis' proprietary epigenome-modulation approach represents a durable scientific differentiation: a platform technology can generate multiple candidates, accelerate discovery, and create sustained R&D optionality. Platform focus supports repeatable pipeline expansion and long-term competitive advantages in specialty biopharma.
Focus On Rare & Intractable DiseasesConcentrating on rare and intractable indications places the company in pockets of persistent unmet need where scientific breakthroughs can translate to durable clinical demand, clearer regulatory pathways, and stronger partner interest, supporting a long-term commercial and licensing strategy.
Conservative Reported LeverageVery low reported debt reduces immediate refinancing and interest-rate pressure, preserving financial flexibility for R&D spending or partnerships. Conservative leverage lowers insolvency risk and gives management structural optionality when raising capital for clinical programs.
Bears Say
Minimal-to-zero RevenueSustained absence of meaningful revenue means the business lacks operating cash generation and product-market validation; the company remains fully dependent on external funding to advance programs, which is a durable risk to sustainability and long-term autonomous growth.
Large Recurring Net LossesConsistent multi-year net losses materially erode equity and limit reinvestment capacity. Persistent losses signal prolonged pre-revenue development stage, increasing funding frequency and dilution risk, and reducing the company's ability to scale operations without significant external capital over the medium term.
Persistent Cash Burn And Weak Cash GenerationOngoing negative operating and free cash flows create structural liquidity pressure and reliance on capital markets or partners. Worsening cash burn in 2025 raises the probability of financing needs within months, constraining strategic choices and increasing execution risk for long-term clinical programs.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥30.00 and its highest was ¥97.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.33B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Aug 10, 2026 which is in 14 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on May 14, 2026. The company reported -¥3.64 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 104,124,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.64 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―